

1 **Integration of high-content fluorescence imaging into the metabolic**  
2 **flux assay reveals insights into mitochondrial properties and**  
3 **functions**

4

5 Andrew C. Little<sup>1,2†</sup>, Ilya Kovalenko<sup>3†</sup>, Laura E. Goo<sup>1,2</sup>, Hanna S. Hong<sup>2,3</sup>, Samuel A. Kerk<sup>2,3</sup>, Joel  
6 A. Yates<sup>1,2</sup>, Vinee Purohit<sup>2,3</sup>, David B. Lombard<sup>2,4</sup>, Sofia D. Merajver<sup>1,2</sup>, Costas A. Lyssiotis<sup>2,3,5\*</sup>

7

8 <sup>1</sup> Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI  
9 48109, USA

10 <sup>2</sup> Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA

11 <sup>3</sup> Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA

12 <sup>4</sup> Department of Pathology and Institute of Gerontology, University of Michigan, Ann Arbor, MI 48109, USA

13 <sup>5</sup> Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor,  
14 MI 48109, USA

15

16 †Denotes equal contribution to study

17 \*e-mail: [clyssiot@med.umich.edu](mailto:clyssiot@med.umich.edu)

18 **SUMMARY**

19 Metabolic flux technology with the Seahorse bioanalyzer has emerged as a standard technique  
20 in cellular metabolism studies, allowing for simultaneous kinetic measurements of respiration  
21 and glycolysis. Methods to extend the utility and versatility of the metabolic flux assay would  
22 undoubtedly have immediate and wide-reaching impacts. Herein, we describe a platform that  
23 couples the metabolic flux assay with high-content fluorescence imaging to simultaneously  
24 enhance normalization of respiration data with cell number; analyze cell cycle progression;  
25 quantify mitochondrial content, fragmentation state, membrane potential, and mitochondrial  
26 reactive oxygen species. Integration of fluorescent dyes directly into the metabolic flux assay  
27 generates a more complete data set of mitochondrial features in a single assay. Moreover,  
28 application of this integrated strategy revealed insights into mitochondrial function following  
29 PGC1a and PRC1 inhibition in pancreatic cancer and demonstrated how the Rho-GTPases  
30 impact mitochondrial dynamics in breast cancer.

31 **KEYWORDS**

32 Mitochondria, Bioenergetics, Metabolism, Reactive Oxygen Species, Image Analysis, XF Assay,  
33 Seahorse, Cytation5, Agilent, BioTek

## 34 INTRODUCTION

35 A primary output of cellular metabolism is chemical energy in the form of adenosine  
36 triphosphate (ATP). The major bioenergetic pathways that generate ATP in a cell are glycolysis  
37 and mitochondrial respiration<sup>1,2</sup>. Production of ATP from the mitochondria is coupled to the  
38 generation of reducing power in the tricarboxylic acid (TCA) cycle, and the respiration-  
39 dependent formation of a proton gradient by the electron transport chain (ETC).

40 While ATP generation is the most well-described role of the mitochondria, this multi-purpose  
41 organelle performs several additional important cellular functions<sup>3-6</sup>. Metabolic outputs of  
42 mitochondrial metabolism directly regulate signal transduction, gene expression, and cell death.  
43 Indeed, it is now established that mitochondrial metabolism impacts numerous physiological and  
44 pathophysiological states, including development, cancer, immune recognition and surveillance,  
45 and blood glucose control to name a few<sup>6-10</sup>. The widespread influence of mitochondria in health  
46 and disease underscores the importance of continued development of strategies to fully  
47 characterize mitochondrial metabolism and function.

48 While recent emerging technologies have permitted more precise examination of mitochondrial  
49 functions and properties, each of these techniques are typically performed independently<sup>11,12</sup>.  
50 This is problematic in the sense that mitochondria are rapidly undergoing (bio)chemical,  
51 morphological, physiochemical, thermodynamic, and other changes at any given time; making  
52 experiment-to-experiment comparisons challenging if the measurements are not simultaneous.  
53 Therefore, capturing bioenergetic and functional data in a single multifunctional assay has the  
54 potential to yield greater, more controlled, and more precise mitochondrial information. Here we  
55 describe an integrated platform that utilizes bioenergetic profiling technology alongside imaging  
56 of mitochondrial functions and properties to formulate a more complete data set from a single  
57 experiment.

58 Metabolic flux technology using the Seahorse Bioanalyzer has emerged as an industry standard  
59 to assess the bioenergetic state of cells *in vitro/ex vivo*. It simultaneously measures pH and  
60 oxygen concentration in media as a function of time. These measurements provide a baseline  
61 surrogate for glycolytic activity as extracellular acidification rate (ECAR), that is media pH  
62 reflecting lactic acid abundance, and mitochondrial respiration or oxygen consumption rate  
63 (OCR), as determined by the extracellular oxygen level. In addition, metabolic flux technology  
64 can also provide information on the bioenergetic properties and functional status of  
65 mitochondria. For example, mitochondrial poisons can be used to infer the bioenergetic  
66 flexibility of a cell, activity of ETC complexes, and maximal respiration capacity. Indeed, the  
67 simplicity, convenience, robustness, and sensitivity of the metabolic flux assay have made it a  
68 technology of choice for many laboratories<sup>13-17</sup>.

69 Despite the widespread use of the Seahorse Bioanalyzer technology, acquisition of reliable data  
70 requires effective normalization strategies to correct for cell density. Multiple normalization  
71 methodologies have been used with varying degrees of acceptance by the research community.  
72 Examples include normalization to post-assay protein harvest or post-assay cell counting,  
73 normalization to pre-assay cell counting<sup>18</sup>, or normalization via one of a variety of chemical  
74 colorimetric or fluorometric readouts (e.g. MTT, ATPGlo, WST-1). Recent adaptations to the  
75 metabolic flux assay have incorporated nuclei fluorescent staining (Hoechst dye) and  
76 subsequent imaging with the BioTek Cytation 5 (BioTek, VT, USA) to more adequately control  
77 for cell number<sup>19</sup>. Herein, we optimize and extend this concept, as nuclei staining with DAPI or  
78 Hoechst dyes can also be applied to determine cell-cycle analysis<sup>20,21</sup>; an important cellular  
79 characteristic when examining drug responses in high-throughput screens. Importantly,  
80 mitochondrial bioenergetics have been previously shown to coordinate with cell cycle


81 dynamics<sup>22,23</sup>, further supporting the use of nuclei counterstaining in conjunction with the  
82 metabolic flux assay.

83 The use of nuclear stains can be valuable not only for cell counting, but for generation of nuclei  
84 masks to permit localized image analysis of fluorescent events in a distance constrained fashion  
85 (e.g. 10 $\mu$ m from nuclei mask); allowing quantification of secondary fluorescent signals at single-  
86 cell resolution. For instance, we have applied fluorescent staining of mitochondria via the  
87 MitoTracker Red cell dye and use proximity to the nucleus to quantify mitochondrial content.  
88 MitoTracker Red is actively sequestered and retained in mitochondria<sup>24</sup>, a process that is initially  
89 dependent on an intact mitochondrial membrane potential<sup>25,26</sup>. In addition to basic identification  
90 and quantification of mitochondria, we utilize MitoTracker dye in combination with high-content  
91 imaging to analyze mitochondrial fragmentation as an added feature integrated into our analysis  
92 pipeline<sup>26,27</sup>.

93 Additional fluorescence-based dyes are similarly available to measure discrete mitochondrial  
94 parameters, including membrane potential ( $\Delta\psi_m$ ) and mitochondrial reactive oxygen species  
95 (mtROS).  $\Delta\psi_m$  is generated by the proton pumping complexes of the ETC. The energy “stored”  
96 in the  $\Delta\psi_m$  is ultimately used to drive ATP production by complex V. While moderate fluctuations  
97 in the  $\Delta\psi_m$  can reflect normal functioning of mitochondria, sustained increases or drops can lead  
98 to mitochondrial pathology and/or target mitochondria for degradation. To build in the detection  
99 of  $\Delta\psi_m$  into our imaging platform, we utilized the fluorescent dye tetramethylrhodamine ethyl  
100 ester (TMRE). TMRE is sequestered in the inner membrane space (IMS) by active mitochondria  
101 based on its negative charge. Depletion of the  $\Delta\psi_m$  leads to loss of sequestration and signal.

102 Mitochondria are one of the primary sources of reactive oxygen species (ROS), which have  
103 been characterized to play important roles in physiological and pathophysiological processes<sup>28-</sup>  
104 <sup>30</sup>. The partial reduction of oxygen by the ETC leads to the formation of superoxide, a potent  
105 mitochondrial ROS (mtROS). MitoSOX is a mitochondrially targeted fluorescent dye<sup>11</sup> that is  
106 oxidized to ethidium by superoxide. The ethidium then intercalates into mitochondrial DNA and  
107 thus produces fluorescence<sup>31</sup>.

108 In this report, we describe a method that integrates the analysis of mitochondrial bioenergetics  
109 with mitochondrial properties, by implementing a variety of chemical fluorescent stains and high-  
110 content imaging into the Seahorse metabolic flux assay. This includes image analysis for cell  
111 number normalization and cell cycle distribution, along with mitochondria quantity, localization,  
112 fragmentation, membrane potential, and ROS (**Fig. 1**). We established the utility of this novel  
113 methodology in human breast and pancreatic cancer cell lines using a variety of  
114 pharmacological probes, including those that perturb nuclear content and mitochondrial  
115 functions, and respiration deficient pancreatic cancer cells. Then, we further extended the utility  
116 of our platform by interrogating mitochondrial content and function following genetic knockdown  
117 of the mitochondrial master regulatory proteins PGC1a and PRC1. Finally, application of this  
118 strategy yielded insights into the role of Rho-GTPases in mitochondrial dynamics in breast  
119 cancer. While the roles of the Rho-like family of Rho-GTPases in breast cancer progression  
120 were well characterized, our study is the first to determine their role in the regulation of  
121 mitochondrial content, fragmentation, and respiratory capacity<sup>32-36</sup>. Collectively this study  
122 enhances the utility of the metabolic flux assay and provides a more complete platform to study  
123 mitochondrial biology from multiple dimensions, simultaneously.



124

125 **Fig. 1 Platform to integrate the metabolic flux assay with high content imaging.** Schematic overview of the  
126 integration of the metabolic flux assay with high-content fluorescent imaging and data analysis workflow. At the  
127 instrument level, cells are processed using the Seahorse metabolic flux assay and immediately stained with a variety  
128 of nuclear and mitochondrial dyes, which is completely integrated in the Seahorse bioanalyzer assay. The plates  
129 are then abstracted and imaged on a Cytation5 Automated Imager for downstream image analysis and interpretation. At  
130 the biochemical level, the metabolic flux assay provides OCR and ECAR data and information on other mitochondrial  
131 bioenergetic properties (by Mito Stress Test). The cells are then stained with nuclear and mitochondrial dyes that  
132 provide information on the cellular properties noted.

## 133 METHODS

134 **Cell culture.** PA-TU-8902, MIA PaCa2, S2-013, and T3M4 pancreatic cancer cell lines were  
135 cultured in DMEM supplemented with 10% FBS. S2-013 p<sup>0</sup> cells were supplied additionally with  
136 10 μg/ml EtBr, 100 μg/ml pyruvate and 50 μg/ml uridine. The VARI068 breast cancer cell line  
137 was maintained in RPMI1640 supplied with 10% FBS. Cell lines were STR profiled and routinely  
138 tested for mycoplasma.

139 **Chemicals and probes.** FCCP, oligomycin, rotenone, antimycin A, TBH70X, tert-Butyl  
140 hydroperoxide solution (Luperox), taxol, and Poly-L-Lysine (mol wt 70,000-150,000, 0.01%)  
141 were obtained from Sigma. Hoechst 33342, Mitotracker DeepRed, MitoSOX, and SYTOX Green  
142 were from ThermoFisher Scientific. TMRE was from Abcam. All compounds were stored at -  
143 20°C except Taxol and Hoechst (4°C). Dyes were stored protected from light. FCCP, Rotenone,  
144 Antimycin A, Hoechst, MitoTracker DeepRed, and SYTOX were stored at -20°C, TMRE was  
145 pre-diluted at 10 μM in media (10X) and aliquoted for single use. MitoSOX was likewise  
146 aliquoted for single use.

147 **shRNA constructs and viral transduction.** pLKO lentiviral vectors were ordered as bacterial  
148 glycerol stocks from Sigma, MISSION® shRNA Bacterial Glycerol Stock, cat# SHCLNG-  
149 NM\_013261. The shNT sequence was subcloned into pLKO backbone vector. The references  
150 for the sequences are provided in Supplementary Table 1. Viral particles were produced by the  
151 University of Michigan Vector Core. T3M4 cells were transduced with the addition of polybrene  
152 (Sigma) to 8µM final concentration. Cells were selected with 1 µg/mL puromycin (Sigma) for 3  
153 days. Following selection, transduced T3M4 cells were seeded at 20,000 cells/well for the  
154 metabolic flux-imaging assay as described below. Remaining cells were processed for qPCR.

155 **RNA isolation and qPCR.** 10<sup>6</sup> cells were lysed and RNA isolated using the RNAeasy kit  
156 (Qiagen) according to the manufacturer's instructions. 1µg of total RNA was added for cDNA  
157 synthesis using the iScript cDNA Synthesis Kit (Bio-Rad) following the manufacturer's protocols.  
158 For qPCR, Fast SYBR Green Master Mix (ThermoFisher Scientific) was used, and amplification  
159 was detected with an Applied Biosystems QuantStudio3 Real-Time PCR System. The  
160 sequences of the primers used for the amplification are provided in the Supplementary Table 2.

161 **Metabolic flux assays.** Adherent cells were seeded at 2x10<sup>4</sup> cells/well in normal growth media  
162 (cell line specific) in a Seahorse XF96 Cell Culture Microplate. To achieve an even distribution  
163 of cells within wells, plates were rocked at 25°C for 20-40 minutes. For each staining group, one  
164 extra well on the outer perimeter of the plate was seeded to calibrate image acquisition  
165 parameters. The plate was then incubated at 37°C overnight to allow the cells to adhere. The  
166 following day, growth media was exchanged with Seahorse Phenol Red-free DMEM and either  
167 basal OCR was measured (for wells that were to be imaged with mitochondrial dyes, see  
168 Imaging section below) or an XF Cell Mito stress test (Agilent) was performed according to the  
169 manufacturer's instructions. In both cases, the last injection port was used for cell stain/dye  
170 injection. Upon completion of the Seahorse assay, cells were washed three times with pre-  
171 warmed phenol-free DMEM media (no FBS) and transferred to the Cytation5 for imaging.


172 For cells grown in suspension, 10<sup>5</sup> cells/well were added to a poly-lysine coated Seahorse XF96  
173 Cell Culture Microplate in Phenol Red-free DMEM based assay media. The plate then was  
174 centrifuged at 300g for 30 minutes with gentle acceleration and deceleration. The plate is then  
175 rotated 180° and the centrifugation repeated. Immediately following completion of the  
176 centrifugation, OCR was measured or an XF Cell Mito stress test was performed followed by  
177 imaging in the Cytation5 as above; schematic of assay workflow can be visualized in  
178 **Supplemental Figure 1A.**

179 **High Content Imaging.** Imaging was carried out using a Cytation5 Cell Imaging Multi-Mode  
180 Reader (BioTek, VT, USA). The environment was controlled at 5% CO<sub>2</sub> and 37°C. Hoechst  
181 (1µg/mL final concentration) was imaged using a 365nm LED in combination with an EX 377/50  
182 EM 447/60 filter cube. SyTOX Green was imaged using a 465nm LED in combination with an  
183 EX 469/35 EM 525/39 filter cube. TMRE (1µM final concentration) and MitoSOX Red (5µM final  
184 concentration) were imaged using a 523nm LED in combination with an EX 531/40 EM 593/40  
185 filter cube. MitoTracker DeepRed (200nM final concentration) was imaged using a 623nm LED  
186 in combination with an EX 628/40 EM 685/40 filter cube. Dyes were delivered at the end of the  
187 XF Cell Mito stress test from Port D at 10X to the entire plate. Cytation 5 image  
188 excitation/emissions spectra utilized for imaging of various fluorescent stains are depicted in  
189 **Supplemental Figure 1B.** Image analysis was completed using Gen5 software (BioTek).  
190 Example of Gen5 nuclei masking and secondary fluorescent signal masking algorithms can be  
191 observed in **Supplemental Fig. 1C.**

192 **RESULTS**

193 **Integration of fluorescent-based nuclear imaging with the Seahorse metabolic flux assay.**

194 *Normalization of Cell Number.* The Seahorse metabolic flux assay is a rapid and robust  
 195 methodology to measure oxygen consumption rate (OCR) and extracellular acidification rate  
 196 (ECAR) of living cells in culture. Due to the sensitivity of the Seahorse XF analyzer to measure  
 197 small changes in OCR and ECAR, it is critical that data are adjusted to account for well to well  
 198 variability in cell number. To this end, we set forth to develop a high-content fluorescent  
 199 imaging-based strategy using nuclear staining to quantify cell number directly after the  
 200 metabolic flux assay (**Fig. 1**). In this iteration of our platform, we first run the Seahorse Mito  
 201 Stress Test assay, in which OCR is measured at baseline and then following sequential  
 202 administration of mitochondrial poisons from the instrument ports. After completion of the assay,  
 203 we deliver the nuclear staining Hoechst dye via the fourth, and otherwise empty, port to live  
 204 cells. The plate is then washed, and nuclei are counted on a Cytation5 Cell Imaging Multi-Mode  
 205 Reader.



206  
 207 **Fig. 2 Integration of fluorescent-based nuclear imaging with the Seahorse metabolic flux assay.** (A) T3M4  
 208 cells were seeded in increasing densities in the Seahorse XF plate and processed through the XF assay for OCR and  
 209 plotted. (B) OCR values were corrected for and plotted against manually counted cell seeding densities. Statistical  
 210 significance determined by one-way ANOVA; \* $p < 0.05$ , \*\* $p < 0.01$ . (C) OCR measurements were corrected for  
 211 fluorescently counted nuclei (i.e. Hoechst+ object) and plotted against seeded cell densities. (D) OCR data (empty  
 212 circle) extrapolated from individual columns of the XF plate display significant variation at the edge columns (i.e.  
 213 columns 2 and 11), while no changes are observed in nuclei distribution (grey circle). Statistical significance  
 214 determined by two-way ANOVA; \* $p < 0.05$ , \*\*\* $p < 0.001$ . (E) Cell cycle analysis distribution of taxol treated cells,  
 215 identified through nuclei fluorescent imaging (e.g. Hoechst+ object). (F) Post hoc distribution analysis of cells treated  
 216 with increasing concentrations of taxol and their respective nuclei staining intensity (A.U.; arbitrary fluorescent units).  
 217 (G) Image analysis of nuclei size via fluorescently labeled nuclei post taxol treatment. (H) OCR values corrected for  
 218 fluorescently identified nuclei are increased post taxol treatment. Statistical significance in G,H determined by  
 219 Student's T-test; \*\*\* $p < 0.001$ . All experiments were the result of  $\geq 2$  independent experiments.

220 Initially, to compare the accuracy of our nuclei identified through image analysis versus cell  
 221 seeding densities at plating, we seeded serial diluted T3M4 pancreatic cancer cells (from 1,500  
 222 to 50,000 cells/well) in XF 96 well plates for Seahorse analysis, nuclei counterstaining, and

223 fluorescent imaging. As expected, we observe increases in raw OCR and ECAR values with  
224 increasing cells seeded (**Fig. 2A, Supplementary Fig. 2A,B**). When normalizing OCR values  
225 according to cells seeded, we observe significant variation (**Fig. 2B**). In contrast, cell  
226 normalization using fluorescently labeled nuclei offered more consistent OCR values in the  
227 3,000 to 50,000 cell seeded range (**Fig. 2C**). We do not observe significant variation in  
228 normalized ECAR values between the cell counting and nuclei labeling strategies with  
229 increasing cell densities (**Supplementary Fig. 2C,D**).

230 Furthermore, when plotting OCR values per nuclei relative to the plate column, we noted  
231 discrepancies in data acquired from wells at the edge of the XF 96 well plate (**Fig. 2D**). We  
232 hypothesized that this resulted from unequal distribution of cells within the well, and in  
233 particular, near to the center of the well where the Seahorse microchamber measures oxygen  
234 concentration (**Supplementary Fig. 3A**). Indeed, we found that cells in the wells at the  
235 perimeter of the plate are more likely to accumulate at the edge of the wells during the  
236 centrifugation process, thus artifactually lowering OCR values. Because we were unable to  
237 correct for this artifact using nuclei counting, we employ the interior columns/rows of the  
238 Seahorse plate for experimentation. Similarly, for assay well for normalization by nuclei  
239 counting, we utilize the cells in the center of the well (schematically represented in  
240 **Supplementary Fig. 3B**).

241 *Cell Cycle Analysis.* Nuclei staining intensity can be used to infer the stage of the cell cycle<sup>20,21</sup>.  
242 Therefore, we sought to determine if we could integrate this analysis to the XF-Cytation5  
243 platform. To this end, we treated T3M4 pancreatic cancer cells across a dose range of taxol, an  
244 FDA approved chemotherapeutic (e.g. Paclitaxel) which arrests cells in G2/M phase of the cell  
245 cycle due to its microtubule polymerization inhibiting properties<sup>37,38</sup>. Of note, at the doses  
246 examined taxol exhibited cell cycle arrest without toxicity (**Supplemental Fig. 4A,B**). Nuclear  
247 staining intensity was then collected and used to demonstrate that taxol induces a dose-  
248 dependent accumulation of cells in the G2/M phase of the cell cycle (**Fig. 2E,F**). Similarly, at the  
249 highest dose examined, we also observed a significant increase in nuclear size (**Fig. 2G**),  
250 demonstrating another utility for our imaging platform. Finally, we observed increased OCR in  
251 T3M4 cells that have been treated with taxol, a previously described feature of taxol  
252 administration<sup>20</sup> (**Fig. 2H**). These data support the utility of nuclei counterstaining and imaging to  
253 assess cell cycle and nuclear size post metabolic flux assay.


## 254 **Integration of fluorescent high-content imaging of mitochondria into the metabolic flux** 255 **assay workflow.**

256 OCR data provide a readout for total respiration of the cells within a well. This is impacted by  
257 both the number and activity of the mitochondria in the cells. The latter is related in part to the  
258 structural properties of the mitochondria, where fused mitochondrial networks tend to be more  
259 respiratory than fissioned mitochondria<sup>39,40</sup>. The location of mitochondria within a cell has also been  
260 reported to impact their function<sup>41,42</sup>. Furthermore, heterogeneity in mitochondrial density,  
261 structure, location, and function also exists on a cell to cell basis within a population of cells in a  
262 well. Therefore, we hypothesized that a more complete understanding of this information would  
263 provide considerable utility in accurately characterizing mitochondrial function and OCR output  
264 from the metabolic flux assay. We therefore adapted our high-throughput imaging platform to  
265 capture these parameters by incorporating a series of mitochondrial dyes, delivered in a manner  
266 akin to the delivery of the nuclear dye described above, followed by image analysis.

267 *Normalization of OCR Data to Mitochondrial Content.* We set forth to image mitochondrial  
268 content and localization and to evaluate the relationship between these parameters and OCR.  
269 To this end, we empirically tested a panel of Mitotracker dyes with T3M4 pancreatic cancer cells  
270 plated in the Seahorse 96XF cell plate. Mitotracker Deep Red was identified as the most



271 consistent and robust probe to visualize mitochondria, as it readily retained bright fluorescence  
 272 in live cell formats as well as post fixation (**Supplementary Fig. 5**). Specifically, it exhibited the  
 273 highest signal/background ratio in the Seahorse XF cell plate, was fixable, and readily integrates  
 274 into our Seahorse workflow.



275  
 276 **Fig. 3 Analysis of mitochondrial quantity and fragmentation downstream of the metabolic flux assay. (A)**  
 277 Hoechst+ nuclei corrected OCR data post mitochondrial stress test (“-MS” designation; e.g. S2-013-MS) or  
 278 measurements of basal OCR values (i.e. S2-013) in wild type S2-013 cells or S2-013-p0 (Rho0) cells. **(B)** OCR  
 279 values corrected for fluorescent nuclei plotted against total fluorescently identified mitochondria (i.e. MitoTracker  
 280 positive arbitrary fluorescent units; A.U.). **(C)** OCR values normalized for nuclei in shNT (non-targeting), shPRC1, or  
 281 shPGC1 $\alpha$  T3M4 cells, plotted against fluorescently identified mitochondria (MitoTracker positive A.U.). **(D)** OCR  
 282 values in shNT, shPRC1, or shPGC1 $\alpha$  T3M4 cells corrected for total fluorescently identified mitochondria (e.g. Mito  
 283 Normalized; MitoUnit). Statistical significance determined by one-way ANOVA; n.s., non-significant; \*\*\*p<0.001. **(E)**  
 284 Hoechst+ nuclei corrected OCR values post Antimycin A treatment. Statistical significance determined by one-way  
 285 ANOVA; \*\*\*p<0.001. **(F)** Overall levels of granulated (black) or fragmented (grey) mitochondria post Antimycin A  
 286 treatment. Statistical significance determined by two-way ANOVA; \*\*\*p<0.001. **(G)** Hoechst+ nuclei corrected OCR  
 287 values of WT, RhoA KO, or RhoC KO VARI068 breast cancer cells. Statistical significance determined by one-way  
 288 ANOVA; \*\*\*p<0.001 vs WT; ####p<0.001 vs RhoA-KO. **(H)** Levels of fragmented mitochondria in WT or RhoA/C-KO  
 289 VARI068 cells. Statistical significance determined by one-way ANOVA; \*\*\*p<0.001. All experiments were the result of  
 290  $\geq 2$  independent experiments.


291 To demonstrate the utility of this approach, we generated a Rho0 (p0) S2-013 pancreatic cancer  
 292 cell line (S2-013-p0) with severely depleted mitochondrial DNA resulting from prolonged culture  
 293 in ethidium bromide<sup>43,44</sup>. Depletion of mitochondrial DNA results in the loss of a functional ETC  
 294 and thus the ability of mitochondria to maintain their  $\Delta\psi_m$  or respire. As expected, S2-013-p0  
 295 cells completely lack a respiratory profile (**Fig. 3A**) and have greatly diminished Mitotracker  
 296 Deep Red staining (**Fig. 3B; Supplementary Fig. 6A**), the latter of which requires  $\Delta\psi_m$  to be  
 297 retained in the IMS. No changes in ECAR were detected in S2-013 WT vs p0 cells  
 298 (**Supplementary Fig. 6B**). These results, using an artificial system of mitochondrial depletion,  
 299 illustrate the utility our imaging platform to capture information on mitochondrial content as well  
 300 as function.

301 To extend our imaging platform to a system with a less extreme mitochondrial defect, we  
 302 employed a genetic approach to deplete mitochondria in a confined timeframe. Protein regulator  
 303 of cytokinesis 1 (PRC1) and peroxisome proliferator-activated receptor gamma coactivator 1-

304 alpha (PGC-1 $\alpha$ ) are master regulators of mitochondrial biogenesis<sup>45-48</sup>. We generated PRC1  
305 and PGC-1 $\alpha$  knockdown T3M4 cells using shRNA (see qPCR results of gene knockdown in  
306 **Supplementary Fig. 7A,B**). Loss of PRC1 or PGC-1 $\alpha$  resulted in fewer overall mitochondria, as  
307 determined by Mitotracker fluorescent staining and quantification (**Supplementary Fig. 7C**). We  
308 then assayed PRC1 and PGC-1 $\alpha$  KO cells for basal levels of OCR and normalized the data to  
309 nuclei number, followed the XF assay with Mitotracker staining and quantification. Using the  
310 nuclei normalization strategy, we observed significantly lower overall OCR values in PRC1 and  
311 PGC-1 $\alpha$  KO cells as compared to their WT counterparts (**Fig. 3C**). In addition, we find fewer  
312 overall mitochondria in the PRC1 and PGC-1 $\alpha$  KO cells, as expected (**Fig. 3C**). Surprisingly,  
313 however, when we apply normalization of the OCR data at per-mitochondrial resolution (e.g.  
314 Mito Normalized; MitoUnit), the normalized data reflects no changes in overall mitochondrial  
315 function in PGC-1 $\alpha$  KO cells and increased OCR in PRC1 KO cells (**Fig. 3D**). These results  
316 suggest that PRC1 and PGC-1 $\alpha$  KO cells harbor normally functioning, albeit fewer,  
317 mitochondria. This could be easily misinterpreted using traditional normalization strategies.  
318 These data strongly support the utilization of mitochondrial quantification as a parallel  
319 normalization technique for OCR data in the metabolic flux assay, as the two normalization  
320 parameters provide different and important outputs.

321 *Mitochondrial Fragmentation Analysis.* Next, we sought to explore the use of Mitotracker  
322 staining as a method to evaluate mitochondrial fragmentation patterns. Mitochondrial  
323 fragmentation has been observed in many settings, including apoptosis, responses to oxidative  
324 stress, neurodegeneration, among various others, and is an important feature of mitochondrial  
325 biology<sup>49-52</sup>. As a positive control, we treated MIA PaCa-2 pancreatic cancer cells with the ETC  
326 complex III inhibitor Antimycin A to induce fragmentation, a previously described feature of its  
327 administration<sup>53</sup>. As expected, we observed a decrease in OCR levels in a dose-dependent  
328 fashion post Antimycin A treatment (**Fig. 3E**). Using Mitotracker staining/imaging and the BioTek  
329 Gen5 spot analysis tool (see BioTek application notes for further detail), we were able to  
330 quantify decreases in granulated mitochondria and increases in fragmented mitochondria  
331 following Antimycin A treatment (**Fig. 3F**). These results confirmed the utility of mitochondrial  
332 image analysis using Mitotracker fluorescent dye for this purpose.

333 The Rho-like family of Rho-GTPases have been well characterized for their participation in the  
334 progression of breast cancer<sup>32,34-36</sup> and the alteration of metabolic phenotype<sup>33</sup>. Therefore, we  
335 next applied our imaging and analysis strategy to explore the potential for fragmented  
336 mitochondria in breast cancer cells that lack either the Rho-like family of Rho-GTPases RhoA or  
337 RhoC, via CRISPR/Cas9 knockout (WT, RhoA KO, RhoC KO) (**Supplementary Fig. 8A**). First,  
338 we examined basal OCR values in the breast cancer patient-derived cell model VARI068<sup>54</sup> and  
339 followed with Mitotracker staining directly into the XF assay. Our data revealed elevated basal  
340 OCR levels in the RhoA KO cell line and lower OCR levels in the RhoC KO cell model (**Fig. 3G**).  
341 No changes in mitochondrial fragmentation/elongation were observed in the more respiratory  
342 RhoA KO cells; in contrast, significantly greater levels of fragmented mitochondria were  
343 observed in the RhoC KO cells (**Fig. 3H**). We confirmed that changes in fragmentation were not  
344 due to altered overall levels of mitochondria (**Supplementary Fig. 8B**). These data illustrate  
345 that quantification of mitochondrial fragmentation via Mitotracker imaging is a robust and useful  
346 method that can be readily integrated into the metabolic flux assay to enrich the overall data set  
347 regarding mitochondrial features.



348  
 349 **Fig. 4 Analysis and quantification of  $\Delta\psi_m$  and mitochondrial ROS.** (A) TMRE fluorescence plotted with respect to  
 350 OCR in T3M4 cells. (B) OCR readout following treatment across a dose range of FCCP in T3M4 cells. (C)  
 351 Distribution analysis of TMRE fluorescence intensity (A.U.) in T3M4 cells. (D) Exponential curve fit of OCR data of  
 352 PA-TU-8902 pancreatic cancer cells treated with either DTBP (di-tert-butyl peroxide; red lines) or hydrogen peroxide  
 353 ( $H_2O_2$ ; blue lines). (E) Violin plots displaying induction of MitoSOX fluorescence (A.U.) following either DTBP or  $H_2O_2$   
 354 treatment. (F) Multi-analysis plot displaying change in OCR values plotted against MitoSOX fluorescence in PA-TU-  
 355 8902 cells post DTBP or  $H_2O_2$  treatment. All experiments were the result of  $\geq 2$  independent experiments.

356 **Fluorescence Staining for Mitochondrial Membrane Potential.** To build detection of  $\Delta\psi_m$  into our  
 357 imaging platform, we utilized the fluorescent dye TMRE. First, we demonstrated that TMRE dye  
 358 fluorescence correlated with increased OCR values, indicative of active mitochondria (Fig. 4A).  
 359 Uncouplers of  $\Delta\psi_m$ , such as FCCP, dissipate the proton gradient. At low concentrations of  
 360 FCCP, the ETC competes to maintain a proton gradient and induce maximal respiration. At  
 361 higher concentrations of FCCP, dissipation of the proton gradient outpaces the capacity of the  
 362 ETC to maintain a gradient, poisoning the mitochondria, and thereby impairing respiration and  
 363  $\Delta\psi_m$ . Treatment of T3M4 cells with FCCP in a dose-dependent fashion demonstrated this  
 364 expected rise and fall in OCR (Fig. 4B, Supplementary Fig. 9A). Similarly, loss of OCR  
 365 correlated with a loss of TMRE uptake by mitochondria, as reflected by decreased TMRE  
 366 intensity quantified from fluorescent image analysis (Fig. 4C); suggesting impaired  
 367 mitochondrial function.

368 **Mitochondrial Reactive Oxygen Species Fluorescence Imaging.** Under physiological conditions,  
 369 the biogenesis and quenching of ROS regulate various cellular processes and are tightly  
 370 controlled<sup>55</sup>. Excessive ROS production, on the other hand, is implicated in numerous

371 pathologies, including aging and cancer. Superoxide is the ROS produced from the  
372 mitochondria by incomplete oxidation of oxygen during respiration. Therefore, we sought to  
373 include detection of mitochondrial superoxide alongside the metabolic flux assay. To measure  
374 mitochondrial superoxide, we used the mitochondrially targeted MitoSOX dye. To induce  
375 mitochondrial superoxide production, we treated the pancreatic cancer cell line PA-TU-8902  
376 with the membrane-targeted radical initiator di-tert-butyl peroxide (DTBP) or hydrogen peroxide  
377 ( $H_2O_2$ ). We then monitored OCR levels, integrated MitoSOX dyes into the metabolic flux assay,  
378 and observed mitochondrial superoxide via MitoSOX fluorescence. We observed that both  $H_2O_2$   
379 and DTBP treatment had a dose-dependent inhibitory effect on OCR levels (**Fig. 4D**). These  
380 data are consistent with prior literature demonstrating that oxidative stress can lead to  
381 diminished basal OCR values<sup>56,57</sup>. Following DTBP or  $H_2O_2$  stimulation, expectedly we  
382 quantified a marked increase in MitoSOX fluorescence (**Fig. 4E**) (representative images can be  
383 seen in **Supplemental Fig. 9B**). Data corrected for overall changes in OCR versus increases in  
384 MitoSOX fluorescence can be observed in **Fig. 4F**. Collectively, these data confirm the utility of  
385 MitoSOX dye incorporation into the XF assay, providing robust quantifiable data regarding  
386 mitochondrial respiration and the generation of ROS.

## 387 **DISCUSSION**

388 Here we present a robust strategy to integrate high-content, high-throughput fluorescent  
389 imaging into the Seahorse metabolic flux assay. This integrated approach aims to build upon  
390 prior efforts to utilize fluorescence-based counterstains for normalization of bioenergetic data<sup>58</sup>,  
391 rather than relying on rudimentary cell number correction strategies. Our pipeline enables the  
392 evaluation of many features in one complete experiment on a single XF96 well plate, increasing  
393 the utility and output of a single experiment while minimizing the potential for plate-to-plate  
394 variability. We initiated this strategy to address observed well to well inconsistencies in the OCR  
395 bioenergetic parameter, as similarly reported by others<sup>19,59</sup>. While classic approaches to  
396 normalize mitochondrial bioenergetic data with total cellular input or quantified cellular protein  
397 may be a quick and efficient, we found these to be inconsistent across experiments and cell  
398 lines. Furthermore, as we detail in **Fig. 2**, the location of cells in a well of a Seahorse plate  
399 impacts OCR. By accounting for both the number of cells (based on nuclear staining), and more  
400 specifically, the number of nuclei in proximity to the sensors, our output provides even greater  
401 precision across columns and wells. Furthermore, we employed nuclear size and staining  
402 intensity to provide information into cell cycle dynamics.

403 Extension of OCR normalization to total mitochondria provides further resolution and more  
404 granular information about mitochondrial capacity, as illustrated in **Fig. 3**. Staining for total  
405 mitochondria is easily achieved through the inclusion of Mitotracker dyes into the metabolic flux  
406 assay workflow. We consider this an important experimental control, as a wide array of  
407 experimental conditions may impact mitochondrial biogenesis or mitochondrial content, which  
408 we have demonstrated affect OCR results. Correction of metabolic flux data using this method  
409 provides additional information alongside nuclei-based cell counting. However, the use of  
410 Mitotracker dyes in this pipeline are not limited to their use as a normalization tool for metabolic  
411 flux data. We also found that the Mitotracker staining patterns readily allow for the identification  
412 and quantification of fragmented mitochondria (**Fig. 3E-H**). Indeed, Mitotracker staining could be  
413 further amended to observe subcellular mitochondrial localization, organelle or molecular co-  
414 localization, fission-fusion dynamics, mitochondrial shape (sphericity), among others.

415 We then applied this platform in two targeted studies. First, we demonstrated that while  
416 knockdown of the master regulators of mitochondrial biogenesis PGC1a and PRC, did result in  
417 less cellular respiration, this was the result of fewer mitochondria, not less active mitochondria

418 **(Fig. 3G,H)**. This illustrates the utility of building in a mitochondrial normalization strategy into  
419 the metabolic flux assay workflow. We then examined how the Rho-like family of Rho-GTPases  
420 impact mitochondrial fragmentation, based on their known role in regulating cytoskeletal  
421 dynamics. And, more specifically, our previous work found that inhibition of RhoC impairs the  
422 metabolic properties of inflammatory breast cancer cells<sup>33</sup>. Application of the MitoTracker  
423 strategy downstream of the metabolic flux assay revealed that RhoC deletion significantly  
424 increases the number of fragmented mitochondria in inflammatory breast cancer cells, which we  
425 hypothesize contributes to the depleted OCR levels **(Fig. 3K,L)**. Future studies are required to  
426 fully characterize the Rho-like Rho-GTPases and their regulation of mitochondrial dynamics.

427 The decision to utilize TMRE and MitoSOX dyes were based on the idea of synthesizing a  
428 broad data set of mitochondrial features that can be analyzed downstream of mitochondrial  
429 respiration on the same cells in the same well. A limitation of the TMRE stain is the requirement  
430 for live cell imaging. Subsequent to this, the cells can be stained with MitoTracker, MitoSOX and  
431 Hoechst, fixed, and entered into the downstream normalization and analysis workflow. Indeed,  
432 we selected a series of dyes with non-overlapping wavelengths **(Supplementary Fig. 1)** so that  
433 this suite of parameters can be simultaneously analyzed on a limited number of wells. As noted,  
434 MitoTracker, MitoSOX and nuclear staining with Hoechst are amenable to fixation and retain  
435 their subcellular localization, and we have had success storing plates for analysis months later.  
436 Accordingly, Seahorse plates can be imaged immediately after analysis (post dye addition) or  
437 stored for downstream analysis if large numbers of plates are being prepared for high-  
438 throughput screening. It is also important to note that cells imaged for MitoTracker, TMRE, and  
439 MitoSOX cannot be the same cells on which the Mito Stress Test is performed. Requisite for the  
440 Mito Stress Test analysis is the use mitochondrial poisons that impact respiration, membrane  
441 potential, oxidative stress, among others. Thus, the staining and analysis protocols need to be  
442 performed in parallel.

443 Finally, we also anticipate that the use of dyes to monitor cellular events beyond those  
444 described herein could be readily amended to this workflow. For example, dyes are available to  
445 analyze lysosomal labeling (LysoTracker), mitochondrial calcium signaling (e.g. Fura-2, Fluo-3),  
446 and/or other oxidative stress parameters (e.g. CellROX)<sup>60</sup>. Similarly, genetically encoded  
447 sensors exist to monitor changes in pH, ATP, redox cofactors (e.g. NADH, NADPH), and  
448 oxidative stress<sup>61-65</sup>, and these could be applied to this workflow. Indeed, the Cytation5 imaging  
449 system permits the use of various filter cube sets allowing visualization of many different  
450 fluorescent channels. Finally, this platform also has the potential to be used for drug screening,  
451 as approaches to disrupt mitochondrial metabolism for cancer therapy, to facilitate mitochondrial  
452 function in aging and other mitochondrial disease, or to promote the turnover of damaged  
453 mitochondria in degenerative conditions remain focal points in the development on novel  
454 therapeutics<sup>66-69</sup>.

455 In total, our platform provides high-resolution normalization strategies for Seahorse data that  
456 encompass nuclei and mitochondrial based fluorescent imaging and quantification. We define  
457 the inclusion of additional mitochondrial stains to generate a robust data set, in one high-  
458 throughput experiment, characterizing mitochondrial biology in a continuous kinetic fashion. This  
459 is imperative in studying mitochondria, as they can rapidly change phenotypes in response to  
460 their environment. Thus, capturing the greatest amount of data in a continuous, rapid manner  
461 will provide more consistent results and may reveal additional mitochondrial characteristics  
462 otherwise not captured in single experiment formats.

463 **ACKNOWLEDGMENTS**

464 We would like to thank Dr. John Dishinger of BioTek for his assistance with designing imaging  
465 and image analysis protocols. Figure 1 and Supplementary Figure 1A and 3B were created  
466 using BioRender.com. C.A.L. was supported by a Pancreatic Cancer Action Network/AACR  
467 Pathway to Leadership award (13-70-25-LYSS); Junior Scholar Award from The V Foundation  
468 for Cancer Research (V2016-009); Kimmel Scholar Award from the Sidney Kimmel Foundation  
469 for Cancer Research (SKF-16-005); a 2017 AACR NextGen Grant for Transformative Cancer  
470 Research (17-20-01-LYSS); and an ACS Research Scholar Grant (RSG-18-186-01). D.L. was  
471 supported by R01GM101171. A.C.L. and S.D.M. were supported by the Breast Cancer  
472 Research Foundation. C.A.L. and S.D.M. were supported by the Rogel Cancer Center core  
473 grant NIH-P30-CA046592-29.

474 **AUTHOR CONTRIBUTIONS**

475 Conceptualization: A.C.L., I.K., C.A.L.; Methodology: A.C.L., I.K., J.A.Y.; Investigation: A.C.L.,  
476 I.K., L.E.G., H.S.H., S.A.K., J.A.Y., V.P.; Visualization: A.C.L., I.K.; Formal Analysis: A.C.L., I.K.;  
477 Manuscript and Figure Preparation: A.C.L., I.K., C.A.L.; Resources: D.L., S.D.M., C.A.L.;  
478 Supervision: S.D.M., C.A.L.; Funding Acquisition: S.D.M., C.A.L.

479 **DECLARATION OF INTERESTS**

480 C.A.L. and I.K. are authors on a provisional patent application concerning the utilization of the  
481 technologies described.

## 482 REFERENCES

- 483 1 Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? *Nature Reviews*  
484 *Cancer* **4**, 891, doi:10.1038/nrc1478 (2004).
- 485 2 Lunt, S. Y. & Heiden, M. G. V. Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell  
486 Proliferation. *Annual Review of Cell and Developmental Biology* **27**, 441-464, doi:10.1146/annurev-  
487 cellbio-092910-154237 (2011).
- 488 3 Chandel, N. S. Mitochondria as signaling organelles. *BMC Biology* **12**, 34, doi:10.1186/1741-7007-  
489 12-34 (2014).
- 490 4 Chandel, Navdeep S. Evolution of Mitochondria as Signaling Organelles. *Cell Metabolism* **22**, 204-  
491 206, doi:<https://doi.org/10.1016/j.cmet.2015.05.013> (2015).
- 492 5 Weinberg, S. E. & Chandel, N. S. Targeting mitochondria metabolism for cancer therapy. *Nature*  
493 *Chemical Biology* **11**, 9, doi:10.1038/nchembio.1712 (2014).
- 494 6 Weinberg, Samuel E., Sena, Laura A. & Chandel, Navdeep S. Mitochondria in the Regulation of  
495 Innate and Adaptive Immunity. *Immunity* **42**, 406-417,  
496 doi:<https://doi.org/10.1016/j.immuni.2015.02.002> (2015).
- 497 7 Nunnari, J. & Suomalainen, A. Mitochondria: In Sickness and in Health. *Cell* **148**, 1145-1159,  
498 doi:<https://doi.org/10.1016/j.cell.2012.02.035> (2012).
- 499 8 Pieczenik, S. R. & Neustadt, J. Mitochondrial dysfunction and molecular pathways of disease.  
500 *Experimental and Molecular Pathology* **83**, 84-92, doi:<https://doi.org/10.1016/j.yexmp.2006.09.008>  
501 (2007).
- 502 9 Suomalainen, A. & Battersby, B. J. Mitochondrial diseases: the contribution of organelle stress  
503 responses to pathology. *Nature Reviews Molecular Cell Biology* **19**, 77, doi:10.1038/nrm.2017.66  
504 <https://www.nature.com/articles/nrm.2017.66#supplementary-information> (2017).
- 505 10 Wallace, D. C. Mitochondria and cancer. *Nature Reviews Cancer* **12**, 685, doi:10.1038/nrc3365  
506 (2012).
- 507 11 Kuznetsov, A. V. *et al.* Mitochondrial ROS production under cellular stress: comparison of different  
508 detection methods. *Analytical and bioanalytical chemistry* **400**, 2383-2390, doi:10.1007/s00216-011-  
509 4764-2 (2011).
- 510 12 Cottet-Rousselle, C., Ronot, X., Lerverve, X. & Mayol, J.-F. Cytometric assessment of mitochondria  
511 using fluorescent probes. *Cytometry Part A* **79A**, 405-425, doi:10.1002/cyto.a.21061 (2011).
- 512 13 Zhang, J. & Zhang, Q. Using Seahorse Machine to Measure OCR and ECAR in Cancer Cells.  
513 *Methods in molecular biology (Clifton, N.J.)* **1928**, 353-363, doi:10.1007/978-1-4939-9027-6\_18  
514 (2019).
- 515 14 Au - Traba, J., Au - Miozzo, P., Au - Akkaya, B., Au - Pierce, S. K. & Au - Akkaya, M. An Optimized  
516 Protocol to Analyze Glycolysis and Mitochondrial Respiration in Lymphocytes. *JoVE*, e54918,  
517 doi:doi:10.3791/54918 (2016).
- 518 15 Sciacovelli, M. *et al.* Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal  
519 transition. *Nature* **537**, 544-547, doi:10.1038/nature19353 (2016).
- 520 16 Blagih, J. *et al.* The energy sensor AMPK regulates T cell metabolic adaptation and effector  
521 responses in vivo. *Immunity* **42**, 41-54, doi:10.1016/j.immuni.2014.12.030 (2015).
- 522 17 Ahler, E. *et al.* Doxycycline alters metabolism and proliferation of human cell lines. *PLoS One* **8**,  
523 e64561, doi:10.1371/journal.pone.0064561 (2013).
- 524 18 Wynn, M. L. *et al.* RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-  
525 Acetylaspartate Production in Inflammatory Breast Cancer Cells. *The Journal of biological chemistry*  
526 **291**, 13715-13729, doi:10.1074/jbc.M115.703959 (2016).
- 527 19 Yookseok Kam, N. J., Joe Clayton, Paul Held, Brian P. Dranka. Normalization of Agilent Seahorse  
528 XF Data by In-situ Cell Counting Using a BioTek Cytation 5. *Agilent Application Notes* (2017).

- 529 20 Ferro, A. *et al.* Blue intensity matters for cell cycle profiling in fluorescence DAPI-stained images.  
530 *Laboratory Investigation* **97**, 615, doi:10.1038/labinvest.2017.13  
531 <https://www.nature.com/articles/labinvest201713#supplementary-information> (2017).
- 532 21 Roukos, V., Pegoraro, G., Voss, T. C. & Misteli, T. Cell cycle staging of individual cells by  
533 fluorescence microscopy. *Nat Protoc* **10**, 334-348, doi:10.1038/nprot.2015.016 (2015).
- 534 22 Finkel, T. & Hwang, P. M. The Krebs cycle meets the cell cycle: Mitochondria and the  
535 G<sub>1</sub>-S transition. *Proceedings of the National Academy of Sciences* **106**,  
536 11825, doi:10.1073/pnas.0906430106 (2009).
- 537 23 Schieke, S. M., McCoy, J. P., Jr. & Finkel, T. Coordination of mitochondrial bioenergetics with G1  
538 phase cell cycle progression. *Cell Cycle* **7**, 1782-1787, doi:10.4161/cc.7.12.6067 (2008).
- 539 24 Gautam, N., Sankaran, S., Yason, J. A., Tan, K. S. W. & Gascoigne, N. R. J. A high content imaging  
540 flow cytometry approach to study mitochondria in T cells: MitoTracker Green FM dye concentration  
541 optimization. *Methods* **134-135**, 11-19, doi:<https://doi.org/10.1016/j.ymeth.2017.11.015> (2018).
- 542 25 Xiao, B., Deng, X., Zhou, W. & Tan, E.-K. Flow Cytometry-Based Assessment of Mitophagy Using  
543 MitoTracker. *Frontiers in Cellular Neuroscience* **10**, doi:10.3389/fncel.2016.00076 (2016).
- 544 26 Westrate, L. M., Drocco, J. A., Martin, K. R., Hlavacek, W. S. & MacKeigan, J. P. Mitochondrial  
545 morphological features are associated with fission and fusion events. *PLoS One* **9**, e95265-e95265,  
546 doi:10.1371/journal.pone.0095265 (2014).
- 547 27 Mitra, K. & Lippincott-Schwartz, J. Analysis of mitochondrial dynamics and functions using imaging  
548 approaches. *Curr Protoc Cell Biol* **Chapter 4**, Unit-4.25.21, doi:10.1002/0471143030.cb0425s46  
549 (2010).
- 550 28 Murphy, Michael P. & Siegel, Richard M. Mitochondrial ROS Fire Up T Cell Activation. *Immunity* **38**,  
551 201-202, doi:<https://doi.org/10.1016/j.immuni.2013.02.005> (2013).
- 552 29 Collins, Y. *et al.* Mitochondrial redox signalling at a glance. *Journal of Cell Science* **125**, 801-806,  
553 doi:10.1242/jcs.098475 (2012).
- 554 30 Murphy, Michael P. How mitochondria produce reactive oxygen species. *Biochemical Journal* **417**, 1-  
555 13, doi:10.1042/bj20081386 (2009).
- 556 31 Kauffman, M. E. *et al.* MitoSOX-Based Flow Cytometry for Detecting Mitochondrial ROS. *React*  
557 *Oxyg Species (Apex)* **2**, 361-370, doi:10.20455/ros.2016.865 (2016).
- 558 32 Little, A. C. *et al.* IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-  
559 GTPase Regulation of Synergistic VEGF/CCL-18 Signaling. *Frontiers in Oncology* **9**,  
560 doi:10.3389/fonc.2019.00456 (2019).
- 561 33 Wynn, M. L. *et al.* RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-  
562 Acetylaspartate Production in Inflammatory Breast Cancer Cells. *Journal of Biological Chemistry*  
563 **291**, 13715-13729, doi:10.1074/jbc.M115.703959 (2016).
- 564 34 Allen, S. G. *et al.* Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC  
565 GTPase Signaling. *Scientific Reports* **6**, 39190, doi:10.1038/srep39190  
566 <https://www.nature.com/articles/srep39190#supplementary-information> (2016).
- 567 35 Wu, M., Wu, Z.-f., Rosenthal, D. T., Rhee, E. M. & Merajver, S. D. Characterization of the roles of  
568 RHOA and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and  
569 aggressive breast cancers. *Cancer* **116**, 2768-2782, doi:10.1002/cncr.25181 (2010).
- 570 36 Merajver, S. D. & Usmani, S. Z. Multifaceted Role of Rho Proteins in Angiogenesis. *Journal of*  
571 *Mammary Gland Biology and Neoplasia* **10**, 291-298, doi:10.1007/s10911-006-9002-8 (2005).
- 572 37 Horwitz, S. B. Taxol (paclitaxel): mechanisms of action. *Annals of oncology : official journal of the*  
573 *European Society for Medical Oncology* **5 Suppl 6**, S3-6 (1994).
- 574 38 Rowinsky, E. K. & Donehower, R. C. Paclitaxel (Taxol). *New England Journal of Medicine* **332**, 1004-  
575 1014, doi:10.1056/nejm199504133321507 (1995).
- 576 39 Westermann, B. Bioenergetic role of mitochondrial fusion and fission. *Biochimica et Biophysica Acta*  
577 *(BBA) - Bioenergetics* **1817**, 1833-1838, doi:<https://doi.org/10.1016/j.bbabi.2012.02.033> (2012).



- 578 40 Westermann, B. Mitochondrial fusion and fission in cell life and death. *Nature Reviews Molecular*  
579 *Cell Biology* **11**, 872, doi:10.1038/nrm3013 (2010).
- 580 41 Detmer, S. A. & Chan, D. C. Functions and dysfunctions of mitochondrial dynamics. *Nature Reviews*  
581 *Molecular Cell Biology* **8**, 870, doi:10.1038/nrm2275 (2007).
- 582 42 Huang, X. *et al.* Sequences flanking the transmembrane segments facilitate mitochondrial  
583 localization and membrane fusion by mitofusin. *Proceedings of the National Academy of Sciences*  
584 **114**, E9863-E9872, doi:10.1073/pnas.1708782114 (2017).
- 585 43 Chandel, N. S. & Schumacker, P. T. Cells depleted of mitochondrial DNA (rho0) yield insight into  
586 physiological mechanisms. *FEBS letters* **454**, 173-176 (1999).
- 587 44 Kukat, A. *et al.* Generation of rho0 cells utilizing a mitochondrially targeted restriction endonuclease  
588 and comparative analyses. *Nucleic acids research* **36**, e44, doi:10.1093/nar/gkn124 (2008).
- 589 45 LeBleu, V. S. *et al.* PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in  
590 cancer cells to promote metastasis. *Nature cell biology* **16**, 992-1003, 1001-1015,  
591 doi:10.1038/ncb3039 (2014).
- 592 46 Scarpulla, R. C., Vega, R. B. & Kelly, D. P. Transcriptional integration of mitochondrial biogenesis.  
593 *Trends in endocrinology and metabolism: TEM* **23**, 459-466, doi:10.1016/j.tem.2012.06.006 (2012).
- 594 47 Gilkerson, R. *et al.* The mitochondrial nucleoid: integrating mitochondrial DNA into cellular  
595 homeostasis. *Cold Spring Harbor perspectives in biology* **5**, a011080,  
596 doi:10.1101/cshperspect.a011080 (2013).
- 597 48 Jornayvaz, F. R. & Shulman, G. I. Regulation of mitochondrial biogenesis. *Essays Biochem* **47**, 69-  
598 84, doi:10.1042/bse0470069 (2010).
- 599 49 Arnoult, D. Mitochondrial fragmentation in apoptosis. *Trends in Cell Biology* **17**, 6-12,  
600 doi:<https://doi.org/10.1016/j.tcb.2006.11.001> (2007).
- 601 50 Knott, A. B., Perkins, G., Schwarzenbacher, R. & Bossy-Wetzler, E. Mitochondrial fragmentation in  
602 neurodegeneration. *Nature Reviews Neuroscience* **9**, 505, doi:10.1038/nrn2417 (2008).
- 603 51 Suen, D. F., Norris, K. L. & Youle, R. J. Mitochondrial dynamics and apoptosis. *Genes &*  
604 *development* **22**, 1577-1590, doi:10.1101/gad.1658508 (2008).
- 605 52 Toyama, E. Q. *et al.* Metabolism. AMP-activated protein kinase mediates mitochondrial fission in  
606 response to energy stress. *Science* **351**, 275-281, doi:10.1126/science.aab4138 (2016).
- 607 53 Wang, J.-B. *et al.* Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation.  
608 *Cancer Cell* **18**, 207-219, doi:<https://doi.org/10.1016/j.ccr.2010.08.009> (2010).
- 609 54 Gilani, R. A. *et al.* UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-  
610 Negative Breast Cancer. *Clinical cancer research : an official journal of the American Association for*  
611 *Cancer Research* **22**, 5087-5096, doi:10.1158/1078-0432.Ccr-15-2158 (2016).
- 612 55 Purohit, V., Simeone, D. M. & Lyssiotis, C. A. Metabolic Regulation of Redox Balance in Cancer.  
613 *Cancers (Basel)* **11**, doi:10.3390/cancers11070955 (2019).
- 614 56 Armstrong, J. A. *et al.* Oxidative stress alters mitochondrial bioenergetics and modifies pancreatic  
615 cell death independently of cyclophilin D, resulting in an apoptosis-to-necrosis shift. *The Journal of*  
616 *biological chemistry* **293**, 8032-8047, doi:10.1074/jbc.RA118.003200 (2018).
- 617 57 Yin, J. *et al.* Toxicity assessment of hydrogen peroxide on Toll-like receptor system, apoptosis, and  
618 mitochondrial respiration in piglets and IPEC-J2 cells. *Oncotarget* **8**, 3124-3131,  
619 doi:10.18632/oncotarget.13844 (2016).
- 620 58 Gerencser, A. A. Metabolic activation-driven mitochondrial hyperpolarization predicts insulin  
621 secretion in human pancreatic beta-cells. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* **1859**,  
622 817-828, doi:<https://doi.org/10.1016/j.bbabi.2018.06.006> (2018).
- 623 59 Gerencser, A. A. *et al.* Quantitative Microplate-Based Respirometry with Correction for Oxygen  
624 Diffusion. *Analytical Chemistry* **81**, 6868-6878, doi:10.1021/ac900881z (2009).

- 625 60 Bassett, J. J. & Monteith, G. R. Genetically Encoded Calcium Indicators as Probes to Assess the  
626 Role of Calcium Channels in Disease and for High-Throughput Drug Discovery. *Adv Pharmacol* **79**,  
627 141-171, doi:10.1016/bs.apha.2017.01.001 (2017).
- 628 61 Hung, Y. P. & Yellen, G. Live-cell imaging of cytosolic NADH-NAD<sup>+</sup> redox state using a genetically  
629 encoded fluorescent biosensor. *Methods Mol Biol* **1071**, 83-95, doi:10.1007/978-1-62703-622-1\_7  
630 (2014).
- 631 62 Zhao, Y. *et al.* SoNar, a Highly Responsive NAD<sup>+</sup>/NADH Sensor, Allows High-Throughput Metabolic  
632 Screening of Anti-tumor Agents. *Cell Metab* **21**, 777-789, doi:10.1016/j.cmet.2015.04.009 (2015).
- 633 63 Tao, R. *et al.* Genetically encoded fluorescent sensors reveal dynamic regulation of NADPH  
634 metabolism. *Nat Methods* **14**, 720-728, doi:10.1038/nmeth.4306 (2017).
- 635 64 Lobas, M. A. *et al.* A genetically encoded single-wavelength sensor for imaging cytosolic and cell  
636 surface ATP. *Nat Commun* **10**, 711, doi:10.1038/s41467-019-08441-5 (2019).
- 637 65 De Michele, R., Carimi, F. & Frommer, W. B. Mitochondrial biosensors. *Int J Biochem Cell Biol* **48**,  
638 39-44, doi:10.1016/j.biocel.2013.12.014 (2014).
- 639 66 Weinberg, S. E. & Chandel, N. S. Targeting mitochondria metabolism for cancer therapy. *Nature*  
640 *chemical biology* **11**, 9-15, doi:10.1038/nchembio.1712 (2015).
- 641 67 Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G. & Galluzzi, L. Mitochondrial  
642 metabolism and cancer. *Cell Research* **28**, 265, doi:10.1038/cr.2017.155 (2017).
- 643 68 Jang, J. Y., Blum, A., Liu, J. & Finkel, T. The role of mitochondria in aging. *The Journal of Clinical*  
644 *Investigation* **128**, 3662-3670, doi:10.1172/JCI120842 (2018).
- 645 69 Sun, N., Youle, R. J. & Finkel, T. The Mitochondrial Basis of Aging. *Molecular cell* **61**, 654-666,  
646 doi:10.1016/j.molcel.2016.01.028 (2016).